Literature DB >> 22553281

Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH.

Roeland Huijgen1, Barbara A Hutten, Iris Kindt, Maud N Vissers, John J P Kastelein.   

Abstract

BACKGROUND: Screening for familial hypercholesterolemia (FH) within affected families is often based on cutoff values for low-density lipoprotein cholesterol (LDL-C). However, the diagnostic accuracy of LDL-C levels is influenced by the magnitude of the LDL-C overlap between FH patients and unaffected relatives. The purpose of the current study was to assess to what extent this overlap is influenced by the severity of specific FH mutations. METHODS AND
RESULTS: Individuals were eligible if they underwent family screening for FH between 2003 and 2010. The entire cohort was then compared with those who were investigated for the presence of the most severe mutations (class 1). The area under the receiver operating characteristics curve and the sensitivity of the 90th percentile of LDL-C were calculated for both cohorts. We included 26 406 individuals, of whom 9169 (35%) carried an FH-causing mutation. In the entire cohort at baseline, mean LDL-C was 4.63 ± 1.44 mmol/L for FH carriers (n=5372) and 2.96 ± 0.96 mmol/L for unaffected relatives (n=15 148); P<0.001. The corresponding operating characteristics curve (95% CI) was 86.6% (85.9%-87.2%), and the cutoff level of LDL-C above the 90th percentile showed a sensitivity of 68.5%. The operating characteristics curve and sensitivity significantly improved when the 5933 individuals tested for class 1 mutations were assessed separately; 96.2% (95.3%-97.1%) and 91.3%, respectively.
CONCLUSIONS: In summary, the overlap in terms of LDL-C levels between those with molecularly proven FH and unaffected relatives is to a large extent because of the high prevalence of modestly severe LDL-receptor mutations in the Netherlands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553281     DOI: 10.1161/CIRCGENETICS.111.962456

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  16 in total

Review 1.  [LDL-cholesterol and cardiovascular events: the lower the better?]

Authors:  Raimund Weitgasser; Michaela Ratzinger; Margit Hemetsberger; Peter Siostrzonek
Journal:  Wien Med Wochenschr       Date:  2016-10-21

Review 2.  Familial Hypercholesterolaemia Diagnosis and Management.

Authors:  Rodrigo Alonso; Leopoldo Perez de Isla; Ovidio Muñiz-Grijalvo; Jose Luis Diaz-Diaz; Pedro Mata
Journal:  Eur Cardiol       Date:  2018-08

Review 3.  Current Treatment of Familial Hypercholesterolaemia.

Authors:  Cameron T Lambert; Pratik Sandesara; Ijeoma Isiadinso; Maria Carolina Gongora; Danny Eapen; Neal Bhatia; Jefferson T Baer; Laurence Sperling
Journal:  Eur Cardiol       Date:  2014-12

Review 4.  2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document.

Authors:  Massimo Volpe; Roberto Volpe; Giovanna Gallo; Vivianne Presta; Giuliano Tocci; Emanuela Folco; Andrea Peracino; Elena Tremoli; Bruno Trimarco
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-18

Review 5.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

6.  Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.

Authors:  Abhimanyu Garg; Sergio Fazio; P Barton Duell; Alexis Baass; Chandrasekhar Udata; Tenshang Joh; Tom Riel; Marina Sirota; Danielle Dettling; Hong Liang; Pamela D Garzone; Barry Gumbiner; Hong Wan
Journal:  J Endocr Soc       Date:  2019-11-29

7.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

8.  Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study.

Authors:  Penny J Norsworthy; Jana Vandrovcova; Ellen R A Thomas; Archie Campbell; Shona M Kerr; Jennifer Biggs; Laurence Game; Anne K Soutar; Blair H Smith; Anna F Dominiczak; David J Porteous; Andrew D Morris; Generation Scotland; Timothy J Aitman
Journal:  BMC Med Genet       Date:  2014-06-23       Impact factor: 2.103

Review 9.  Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.

Authors:  Robert Pears; Michael Griffin; Marta Futema; Steve E Humphries
Journal:  Curr Opin Lipidol       Date:  2015-06       Impact factor: 4.776

10.  Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management.

Authors:  Osman Najam; Kausik K Ray
Journal:  Cardiol Ther       Date:  2015-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.